**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/230

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | ACTION TABLETS | | **REF. NO: NDQD201609104** |
| **DATE RECEIVED:** 2016-09-08 | **LABEL CLAIM:** | Each tablet contains: Acetylsalicylic Acid B.P. 600 mg, Paracetamol B.P. 300 mg and Caffeine Anhydrous B.P. 50 mg. | |
| **BATCH NO.:** 1606056 | **PRESENTATION:** | Off white coloured, circular shaped, biconvex faced tablets, single scored on one face and embossed â€˜ACTIONâ€™ on the other, packed in paper strips of two tablets each in a box carrying 100 tablets. | |
| **MFG. DATE:** Jun. 2016 | **MANUFACTURER:** | BETA Healthcare International Ltd. | |
| **EXP. DATE:**  Jun. 2021 | **ADDRESS:** | Plot No: LR 209/6554, Mogadishu Road, Industrial Area, P. O. Box 42569 - 00100, Nairobi, KENYA. | |
| **CLIENT REF NO:** | **CLIENT:** | Beta Healthcare International Ltd, P. O. Box 42569-00100, Nairobi, KENYA. | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | One Deviates +5.2% | **COMPLIES** |
| **Identification** | HPLC | USP 38 NF 33 Pg 2012 | RT of the major peaks in the assay sample preparation corresponds to those in the assay standard preparation | Super-imposable peak at RT 4.1, 4.7 & 9.5 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | USP 38 NF 33 Pg 2012 | No Tablet Less Than 80.0% | Paracetamol Average | **COMPLIES** |
| **Dissolution** |  |  |  | 97.6% Range | **COMPLIES** |
| **Dissolution** |  |  |  | 93 -100% (RSD = 2.5%; n = 6) | **COMPLIES** |
| **Dissolution** |  |  |  | Aspirin Average |  |
| **Dissolution** |  |  |  | 96.6% Range |  |
| **Dissolution** |  |  |  | 93 - 99% (RSD = 2.6%; n = 6) |  |
| **Dissolution** |  |  |  | Caffeine Average |  |
| **Dissolution** |  |  |  | 93.8% Range |  |
| **Dissolution** |  |  |  | 89 - 98% (RSD = 3.3%; n = 6) |  |
| **Assay** | HPLC | USP 38 NF 33 Pg 2012 | 90.0 - 110.0% | Paracetamol 102.5% (RSD = 1.4%; n = 9) | **COMPLIES** |
| **Assay** |  |  |  | Aspirin 104.1% (RSD = 1.1%; n = 8) | **COMPLIES** |
| **Assay** |  |  |  | Caffeine 98.1% (RSD = 1.4%; n = 6) | **COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| **ANALYST:** | LORNA WANGARI | .......................................................... | DATE: 10-03-2016 |
| **REVIEWER** | DR. GEORGE WANG'ANG'A | .......................................................... | DATE: 26-10-2016 |
| **ANALYST:** | ERNEST MBAE | .......................................................... | DATE: 10-26-2016 |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 11-10-2016 |